The tumor and muscle ratio of CXCR4-IR-783 increased from day 1 and peaked at day 3 post injection of CXCR4-IR-783 in mice bearing F5M2 xenograft (Fig. 4A,B). This evidence concerns the gene CXCR4 and neoplasm.